Face And Body Itch Follow Distinct Nerve Pathways, Study Suggests

Why Scratching a Face Itch Feels Different From Scratching Your Arm, According to Science

Scratch an itch on your arm, and your brain handles it like a routine memo: something is irritating the skin, please scratch. An itch on the face travels a different route through the nervous system, one that appears to blur the boundary between itch and pain in ways scientists are only now beginning to map.

A new study from researchers at North Carolina State University’s College of Veterinary Medicine has identified a previously underappreciated population of facial sensory neurons and chemical signals that may help explain why facial itching behaves differently from body itching. Two types of nerve cells, those producing Substance P and somatostatin, appear to work together to suppress facial itch by recruiting pain-signaling pathways in the brainstem. When something itchy hits the face, the nervous system appears to blend itch and pain signaling, which may dampen the urge to scratch.

That matters for people with stubborn conditions that hit the head and face especially hard, including certain types of eczema, shingles, and a nerve disorder called trigeminal neuralgia. Published in Communications Biology, this research raises the possibility that some treatments based mainly on body-itch pathways may miss important features of facial itch.

Facial Itch Triggers Less Scratching Despite More Nerve Fibers

Researchers who study itch in mice typically inject an itch-causing substance into one of two spots: the back of the neck or the cheek. Mice scratch both areas with their hind paws, allowing direct comparison.

Led by senior author Santosh K. Mishra, the team first reviewed published studies spanning more than a decade, confirming a consistent pattern: mice scratched their cheeks significantly less than their necks across multiple itch-triggering substances. Researchers then ran their own experiments using histamine, the chemical behind allergic reactions in humans, and chloroquine, another known itch-inducer. Two mouse strains were tested to rule out a genetic fluke. In both, cheek scratching was significantly lower than neck scratching after identical injections, and cheek-directed scratching peaked within the first five minutes while neck scratching built more slowly, peaking around 15 minutes.

But the reduced face-scratching wasn’t because the cheek had fewer nerve endings. Microscope examination showed the cheek actually had significantly more nerve fibers, including more itch-sensing fibers, than the back of the neck. Something else was suppressing the itch response on the face.

A Chemical Pathway That Blends Facial Itch and Pain

Researchers zeroed in on Substance P, a chemical messenger long associated with pain signaling. In the nerve clusters serving the torso and limbs, itch-carrying and pain-carrying cells are largely separate populations. In the nerve clusters serving the face, the team found a very different picture.

A significantly higher percentage of facial nerve cells produced both somatostatin, an itch-related chemical, and Substance P simultaneously. In body nerve clusters, only about 3% of skin-connected cells carrying one particular histamine receptor also produced Substance P. In facial nerve clusters, that overlap jumped as high as 22.6%.

To test whether Substance P was actually responsible for suppressing facial itch, the team used mice engineered to lack it. Those mice scratched their cheeks significantly more than normal mice, losing the braking mechanism that keeps facial itch in check, while neck-scratching stayed the same. When a drug blocking the receptor Substance P binds to was used, the same pattern emerged. Two additional experiments ruled out the skin as the source. Injecting the blocker directly into the cheek had no impact on scratching, and mice engineered to lack skin mast cells scratched normally. Both results pointed toward the central nervous system rather than the skin.

Why Common Antihistamines May Not Be Enough for Facial Itch

Research also revealed an unexpected partnership between two histamine receptors, designated HRH1 and HRH3. Previous work had generally associated HRH1 with itch and HRH3 with pain. When either receptor was blocked individually before histamine was injected into the cheek, both the scratching response and the pain-related face-wiping response were eliminated. Neither receptor alone could sustain either response.

Common antihistamines work by blocking a single histamine signal, but this study suggests facial itch may require both histamine receptors to be active simultaneously, on top of the Substance P and brainstem circuitry unique to the face.

Digging into the brainstem, the team found a population of nerve cells that exists in the facial processing region but not in the corresponding area for body signals. These cells carried receptors for both Substance P and BNP, a chemical that promotes itch signaling, positioning them to blend itch and pain simultaneously. Lab-dish experiments confirmed that facial nerve cells released significantly more Substance P than body nerve cells when exposed to histamine.

Small, preliminary experiments in human donor tissue supported these patterns. Nerve clusters from donors showed the same increased overlap of somatostatin and Substance P in facial nerve cells, along with similar shifts in histamine receptor activity, though those results will need further validation given the small sample size.

Researchers caution that the work demonstrates a correlation between the unique chemical signatures and the behavioral outcomes, rather than definitive proof of direct causation. Future studies using cell-specific targeting techniques will be needed to confirm the pathway. Still, the possibility that facial itch runs on fundamentally different wiring than body itch may eventually help explain why conditions affecting the head and face so often involve mixtures of itch and pain that resist standard treatments.

---

Disclaimer: The findings discussed in this article are based on preclinical research conducted primarily in mice. Results have not been tested in human clinical trials and should not be interpreted as medical advice.

---